Sygnature wins grant from N2 Business Growth Fund
A Nottingham based provider of advanced scientific research into new medicines for patients, has successfully applied for a £190,000 grant from the N2 Business Growth Programme. Founded in 2004 in Nottingham, Sygnature Discovery employs over 150 personnel and is located in a purpose-built laboratory facility in the Laurus Building at BioCity. They have become recognised as one of Nottingham’s most successful High Growth businesses and have become the UK’s largest independent provider of integrated drug discovery resource and expertise. Their exciting ‘growth’ strategy is set to continue as Sygnature is scheduled to expand into a brand new £30m flagship building in early 2017.
The grant provided from the N2 Business Growth Fund will enable Sygnature to purchase a series of new pieces of analytical equipment which allow them to continue to operate at the very top of their field. At the same time, they plan to increase their Nottingham based workforce by up to 30%.
Victoria Tabiner, Financial Director at Sygnature was quick to emphasise the importance of the N2 grant, and the positive impact that it will have on their short term growth aspirations, ‘Sygnature is delighted to have secured our recent investment from the N2 Business Growth Fund, we have already set about purchasing new equipment with support of the grant which will allow us to further our research capabilities right here on our Nottingham site.’
The N2 Business Growth Fund remains open for applications, and will support capital investment projects for Nottinghamshire based businesses with a minimum project value of £100,000. Since launching in 2015, the programme has approved grants totalling £1.2m, supporting the creation of over 150 jobs.